An Open-Label, Escalating-Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral CS-0777, Administered for 12 Weeks, in Patients With Multiple Sclerosis.

Trial Profile

An Open-Label, Escalating-Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral CS-0777, Administered for 12 Weeks, in Patients With Multiple Sclerosis.

Completed
Phase of Trial: Phase I

Latest Information Update: 16 Aug 2017

At a glance

  • Drugs CS 0777 (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions
  • Sponsors Daiichi Sankyo Inc
  • Most Recent Events

    • 09 Mar 2011 Actual end date changed from Mar 2010 to Sep 2010 as reported by ClinicalTrials.gov
    • 22 Jun 2010 Actual patient number (32) added as reported by ClinicalTrials.gov.
    • 22 Jun 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top